Drug discovery and development for neglected parasitic diseases

Diseases caused by tropical parasites affect hundreds of millions of people worldwide but have been largely neglected for drug development because they affect poor people in poor regions of the world. Most of the current drugs used to treat these diseases are decades old and have many limitations, including the emergence of drug resistance. This review will summarize efforts to reinvigorate the drug development pipeline for these diseases, which is driven in large part by support from major philanthropies. The organisms responsible for these diseases have a fascinating biology, and many potential biochemical targets are now apparent. These neglected diseases present unique challenges to drug development that are being addressed by new consortia of scientists from academia and industry.

[1]  M. Zvelebil,et al.  Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase. , 2001, European journal of medicinal chemistry.

[2]  M. Sajid,et al.  Schistosomiasis Mansoni: Novel Chemotherapy Using a Cysteine Protease Inhibitor , 2007, PLoS medicine.

[3]  Christian Scheurer,et al.  Identification of an antimalarial synthetic trioxolane drug development candidate , 2004, Nature.

[4]  M. Sajid,et al.  Cysteine proteases of parasitic organisms. , 2002, Molecular and biochemical parasitology.

[5]  Erica Pasini,et al.  Design and synthesis of endoperoxide antimalarial prodrug models. , 2004, Angewandte Chemie.

[6]  M. Cushion,et al.  Parallel solution-phase synthesis of conformationally restricted congeners of pentamidine and evaluation of their antiplasmodial activities. , 2004, Journal of medicinal chemistry.

[7]  David A. Matthews,et al.  Structure of and kinetic channelling in bifunctional dihydrofolate reductase–thymidylate synthase , 1994, Nature Structural Biology.

[8]  S. Croft,et al.  Artemisone--a highly active antimalarial drug of the artemisinin class. , 2006, Angewandte Chemie.

[9]  C. Hansch,et al.  Selective inhibition of Leishmania dihydrofolate reductase and Leishmania growth by 5-benzyl-2,4-diaminopyrimidines. , 1988, Molecular and biochemical parasitology.

[10]  J. McKerrow,et al.  A Cathepsin B-like Protease Is Required for Host Protein Degradation in Trypanosoma brucei* , 2004, Journal of Biological Chemistry.

[11]  Arvind Kumar,et al.  Antileishmanial Activities of Several Classes of Aromatic Dications , 2002, Antimicrobial Agents and Chemotherapy.

[12]  Ximena Aguilera,et al.  Treatment of chronic Chagas' disease with itraconazole and allopurinol. , 1998, The American journal of tropical medicine and hygiene.

[13]  D. Loebenberg,et al.  Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan ParasiteTrypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts , 2000, Antimicrobial Agents and Chemotherapy.

[14]  J. Palmer,et al.  Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. , 1998, Journal of cell science.

[15]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[16]  P. Michels,et al.  Metabolic compartmentation in African trypanosomes. , 1996, Parasitology today.

[17]  F. Cohen,et al.  Searching for New Antimalarial Therapeutics amongst Known Drugs , 2006, Chemical biology & drug design.

[18]  F. Hidalgo-Zarco,et al.  Trypanosomal dUTPases as potential targets for drug design. , 2001, Current protein & peptide science.

[19]  D M Leonard,et al.  Ras farnesyltransferase: a new therapeutic target. , 1997, Journal of medicinal chemistry.

[20]  M. Bogyo,et al.  Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Cumming,et al.  Orally active antimalarial 3-substituted trioxanes: new synthetic methodology and biological evaluation. , 1998, Journal of medicinal chemistry.

[22]  J. McKerrow.  Designing Drugs for Parasitic Diseases of the Developing World , 2005, PLoS medicine.

[23]  D. Chakrabarti,et al.  Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. , 2006, Journal of medicinal chemistry.

[24]  C. Wang.  Validating targets for antiparasite chemotherapy , 1997, Parasitology.

[25]  J. Maertens,et al.  History of the development of azole derivatives. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[26]  C. R. Bagnell,et al.  Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. , 2004, Acta tropica.

[27]  J. Berman,et al.  Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. , 1998, Bulletin of the World Health Organization.

[28]  J. Cumming,et al.  Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. , 1997, Advances in pharmacology.

[29]  M. Nair,et al.  Kwanzoquinones A–G and other constituents of Hemerocallis fulva ‘Kwanzo’ roots and their activity against the human pathogenic trematode Schistosoma mansoni , 2002 .

[30]  C. Naula,et al.  Protein kinases as drug targets in trypanosomes and Leishmania. , 2005, Biochimica et biophysica acta.

[31]  S. Puri,et al.  Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice. , 2006, Journal of Medicinal Chemistry.

[32]  L. Johnson,et al.  Second-generation azole antifungal agents. , 2005, Drugs of today.

[33]  A. Kohn,et al.  Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel. , 2001, The Journal of biological chemistry.

[34]  F. Buckner,et al.  Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. , 2005, Molecular and biochemical parasitology.

[35]  T. Shapiro,et al.  A short synthesis and biological evaluation of potent and nontoxic antimalarial bridged bicyclic beta-sulfonyl-endoperoxides. , 2003, Journal of medicinal chemistry.

[36]  I. Gilbert.  Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. , 2002, Biochimica et biophysica acta.

[37]  B. Meunier,et al.  Preparation and Antimalarial Activities of “Trioxaquines”, New Modular Molecules with a Trioxane Skeleton Linked to a 4‐Aminoquinoline , 2000, Chembiochem : a European journal of chemical biology.

[38]  J. McKerrow,et al.  Cysteine protease inhibitors block schistosome hemoglobin degradation in vitro and decrease worm burden and egg production in vivo. , 1996, Molecular and biochemical parasitology.

[39]  R. McCabe.  Failure of ketoconazole to cure chronic murine Chagas' disease. , 1988, The Journal of infectious diseases.

[40]  Protein prenyltransferases : Isoprenoids - Biosynthesis and role in the regulation of protein function , 1992 .

[41]  B. Burleigh,et al.  The mechanisms of Trypanosoma cruzi invasion of mammalian cells. , 1995, Annual review of microbiology.

[42]  D. Goldberg,et al.  Identification and Characterization of Falcilysin, a Metallopeptidase Involved in Hemoglobin Catabolism within the Malaria Parasite Plasmodium falciparum* , 1999, The Journal of Biological Chemistry.

[43]  P. Wincker,et al.  Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma (Schizotrypanum)cruzi: In Vitro and In Vivo Studies , 1998, Antimicrobial Agents and Chemotherapy.

[44]  Herbert Waldmann,et al.  Therapeutic intervention based on protein prenylation and associated modifications , 2006, Nature chemical biology.

[45]  S. Krishna,et al.  Artemisinins target the SERCA of Plasmodium falciparum , 2003, Nature.

[46]  G H Posner,et al.  Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family. , 1999, Journal of medicinal chemistry.

[47]  I H Gilbert,et al.  Novel inhibitors of Leishmanial dihydrofolate reductase. , 2001, Bioorganic & medicinal chemistry letters.

[48]  D. Goldberg,et al.  Biological roles of proteases in parasitic protozoa. , 2002, Annual review of biochemistry.

[49]  B. Schweitzer,et al.  Dihydrofolate reductase as a therapeutic target , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  S. Krishna,et al.  Artemisinins: mechanisms of action and potential for resistance. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[51]  S. Ward,et al.  Enantiomeric 1,2,4‐Trioxanes Display Equivalent in vitro Antimalarial Activity Versus Plasmodium falciparum Malaria Parasites: Implications for the Molecular Mechanism of Action of the Artemisinins , 2005, Chembiochem : a European journal of chemical biology.

[52]  John R Perfect,et al.  Liposomal amphotericin B: clinical experience and perspectives , 2005, Expert review of anti-infective therapy.

[53]  L. Hardy,et al.  The Roles of Pteridine Reductase 1 and Dihydrofolate Reductase-Thymidylate Synthase in Pteridine Metabolism in the Protozoan Parasite Leishmania major* , 1997, The Journal of Biological Chemistry.

[54]  C L Verlinde,et al.  Glycolysis as a target for the design of new anti-trypanosome drugs. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[55]  B. K. Park,et al.  Novel, potent, semisynthetic antimalarial carba analogues of the first-generation 1,2,4-trioxane artemether. , 1999, Journal of medicinal chemistry.

[56]  David K Williams,et al.  Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. , 2005, Journal of medicinal chemistry.

[57]  P. McCann,et al.  Ornithine decarboxylase as an enzyme target for therapy. , 1992, Pharmacology & therapeutics.

[58]  F. Cohen,et al.  Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. , 2002, Journal of medicinal chemistry.

[59]  L. Gerena,et al.  Convenient Access Both to Highly Antimalaria‐Active 10‐Arylaminoartemisinins, and to 10‐Alkyl Ethers Including Artemether, Arteether, and Artelinate , 2005, Chembiochem : a European journal of chemical biology.

[60]  I. Bathurst,et al.  Medicines for Malaria Venture: sustaining antimalarial drug development. , 2006, Trends in parasitology.

[61]  Ian H. Gilbert,et al.  Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase. , 1999, Journal of medicinal chemistry.

[62]  J. Urbina,et al.  Activity of the New Triazole Derivative Albaconazole against Trypanosoma (Schizotrypanum) cruzi in Dog Hosts , 2004, Antimicrobial Agents and Chemotherapy.

[63]  I. Gilbert,et al.  dUTPase as a platform for antimalarial drug design: structural basis for the selectivity of a class of nucleoside inhibitors. , 2005, Structure.

[64]  I. Gilbert,et al.  2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase. , 2003, Bioorganic & medicinal chemistry.

[65]  Katherine A Brown,et al.  Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. , 2003, Molecular and biochemical parasitology.

[66]  J. Karle,et al.  Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes. , 2005, Journal of medicinal chemistry.

[67]  D. Krogstad,et al.  Pharmacokinetics of the Antimalarial Drug, AQ-13, in Rats and Cynomolgus Macaques , 2004, International journal of toxicology.

[68]  J. Derisi,et al.  Incorporation of an Intramolecular Hydrogen-bonding Motif in the Side Chain of 4-aminoquinolines Enhances Activity against Drug-resistant P. Falciparum , 2022 .

[69]  R. Titus,et al.  Novel Compounds Active against Leishmania major , 2006, Antimicrobial Agents and Chemotherapy.

[70]  P. Rosenthal,et al.  Antimalarial Synergy of Cysteine and Aspartic Protease Inhibitors , 1998, Antimicrobial Agents and Chemotherapy.

[71]  J. K. Wood,et al.  Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[5.2.5. 2]hexadecanes. , 2000, Journal of medicinal chemistry.

[72]  Beth Apsel,et al.  Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei , 2006, Chemical biology & drug design.

[73]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[74]  F. Opperdoes,et al.  Enzymes of carbohydrate metabolism as potential drug targets. , 2001, International journal for parasitology.

[75]  Prashanth Athri,et al.  3D QSAR on a library of heterocyclic diamidine derivatives with antiparasitic activity. , 2006, Bioorganic & medicinal chemistry.

[76]  P. O’Neill,et al.  A medicinal chemistry perspective on artemisinin and related endoperoxides. , 2004, Journal of medicinal chemistry.

[77]  D. Krogstad,et al.  Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. , 1998, Journal of medicinal chemistry.

[78]  A. Chabes,et al.  Trypanosoma brucei CTP synthetase: A target for the treatment of African sleeping sickness , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[79]  C. W. Jefford,et al.  Blood schizontocidal activity of selected 1,2,4-trioxanes (Fenozans) against the multidrug-resistant strain of Plasmodium yoelii nigeriensis (MDR) in vivo , 2006, Parasitology.

[80]  D. Bonn.  New ways with old bones , 2004, The Lancet.

[81]  M. Barrett,et al.  DNA binding affinity of bisguanidine and bis(2-aminoimidazoline) derivatives with in vivo antitrypanosomal activity. , 2006, Journal of medicinal chemistry.

[82]  L. Filardi,et al.  An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. , 1993, Memorias do Instituto Oswaldo Cruz.

[83]  Hugo Albrecht,et al.  Cercarial Elastase Is Encoded by a Functionally Conserved Gene Family across Multiple Species of Schistosomes* , 2002, The Journal of Biological Chemistry.

[84]  I. Gilbert,et al.  The structure-based design and synthesis of selective inhibitors of Trypanosoma cruzi dihydrofolate reductase. , 1999, Bioorganic & medicinal chemistry letters.

[85]  H. Rozenberg,et al.  Total syntheses of Yingzhaosu A and of its C(14)-epimer including the first evaluation of their antimalarial and cytotoxic activities. , 2005, The Journal of organic chemistry.

[86]  D. Boykin,et al.  Enhanced Permeability of the Antimicrobial Agent 2,5-Bis(4-Amidinophenyl)Furan Across Caco-2 Cell Monolayers Via Its Methylamidoxime Prodrug , 2002, Pharmaceutical Research.

[87]  D. Santi,et al.  Thymidylate synthase-dihydrofolate reductase in protozoa. , 1990, Experimental parasitology.

[88]  F. Opperdoes,et al.  Localization of nine glycolytic enzymes in a microbody‐like organelle in Trypanosoma brucei: The glycosome , 1977, FEBS letters.

[89]  T. C. White,et al.  Induction of Resistance to Azole Drugs inTrypanosoma cruzi , 1998, Antimicrobial Agents and Chemotherapy.

[90]  C. Stout.  Induced fit, drug design, and dUTPase. , 2004, Structure.

[91]  M. Gelb,et al.  Thematic review series: Lipid Posttranslational Modifications. Fighting parasitic disease by blocking protein farnesylation Published, JLR Papers in Press, December 7, 2005. , 2006, Journal of Lipid Research.

[92]  S Toba,et al.  Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. , 2000, Chemistry & biology.

[93]  Arvind Kumar,et al.  Anti-pneumocystis activity of bis-amidoximes and bis-o-alkylamidoximes prodrugs , 1996 .

[94]  Yikang Wu.  How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. , 2002, Accounts of chemical research.

[95]  B. K. Park,et al.  Mechanism-based design of parasite-targeted artemisinin derivatives: synthesis and antimalarial activity of new diamine containing analogues. , 2002, Journal of medicinal chemistry.

[96]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.